FI942766A0 - 20-metylsubstituerade D-vitaminderivat - Google Patents

20-metylsubstituerade D-vitaminderivat

Info

Publication number
FI942766A0
FI942766A0 FI942766A FI942766A FI942766A0 FI 942766 A0 FI942766 A0 FI 942766A0 FI 942766 A FI942766 A FI 942766A FI 942766 A FI942766 A FI 942766A FI 942766 A0 FI942766 A0 FI 942766A0
Authority
FI
Finland
Prior art keywords
group
derivatives
methyl
carbon atoms
production
Prior art date
Application number
FI942766A
Other languages
English (en)
Finnish (fi)
Other versions
FI108226B (sv
FI942766A (sv
Inventor
Guenter Neef
Andreas Steinmeyer
Gerald Kirsch
Katica Schwarz
Ruth Thieroff-Ekerdt
Herbert Wiesinger
Martin Haberey
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of FI942766A0 publication Critical patent/FI942766A0/sv
Publication of FI942766A publication Critical patent/FI942766A/sv
Application granted granted Critical
Publication of FI108226B publication Critical patent/FI108226B/sv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI942766A 1991-12-13 1994-06-10 Förfarande för framställning av 20-metylsubstituerade derivat av vitamin D och mellanprodukt för användning vid förfarandet FI108226B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4141746A DE4141746A1 (de) 1991-12-13 1991-12-13 20-methyl-substituierte vitamin d-derivate
DE4141746 1991-12-13
EP9202887 1992-12-14
PCT/EP1992/002887 WO1993012081A1 (de) 1991-12-13 1992-12-14 20-methyl-substituierte vitamin d-derivate

Publications (3)

Publication Number Publication Date
FI942766A0 true FI942766A0 (sv) 1994-06-10
FI942766A FI942766A (sv) 1994-06-10
FI108226B FI108226B (sv) 2001-12-14

Family

ID=6447341

Family Applications (1)

Application Number Title Priority Date Filing Date
FI942766A FI108226B (sv) 1991-12-13 1994-06-10 Förfarande för framställning av 20-metylsubstituerade derivat av vitamin D och mellanprodukt för användning vid förfarandet

Country Status (24)

Country Link
US (1) US5446035A (sv)
EP (1) EP0637299B1 (sv)
JP (1) JP3280975B2 (sv)
KR (1) KR100271462B1 (sv)
CN (1) CN1035177C (sv)
AT (1) ATE138366T1 (sv)
AU (1) AU670585B2 (sv)
CA (1) CA2125476C (sv)
CZ (1) CZ286579B6 (sv)
DE (2) DE4141746A1 (sv)
DK (1) DK0637299T3 (sv)
ES (1) ES2089585T3 (sv)
FI (1) FI108226B (sv)
GR (1) GR3020097T3 (sv)
HU (1) HUT68263A (sv)
IL (1) IL104074A (sv)
MX (1) MX9207101A (sv)
NO (1) NO305949B1 (sv)
NZ (1) NZ246052A (sv)
PL (1) PL171403B1 (sv)
SK (1) SK280450B6 (sv)
TW (1) TW275060B (sv)
WO (1) WO1993012081A1 (sv)
ZA (1) ZA929650B (sv)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4220757A1 (de) * 1992-06-24 1994-01-05 Schering Ag Derivate in der Vitamin D-Reihe mit Modifikationen in der 20-Position, Verfahren zu ihrer Herstellung, Zwischenprodukte für dieses Verfahren, diese Derivate enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
GB9220272D0 (en) * 1992-09-25 1992-11-11 Leo Pharm Prod Ltd Chemical compounds
IL107185A (en) * 1992-10-06 1998-02-22 Schering Ag History of 52-carboxylic acid, processes for their preparation and pharmaceutical preparations containing them
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
US20040167106A1 (en) * 1993-06-04 2004-08-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of a Vitamin D compound
GB9315253D0 (en) * 1993-07-23 1993-09-08 Res Inst Medicine Chem Chemical compounds
US5428029A (en) * 1993-11-24 1995-06-27 Hoffmann-La Roche Inc. Vitamin D3 fluorinated analogs
US5981597A (en) * 1995-02-13 1999-11-09 Trustees Of The University Of Pennsylvania Differentiating agents for the treatment of inflammatory intestinal diseases
CA2246356A1 (en) * 1996-02-13 1997-08-21 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist
DE19619036A1 (de) 1996-04-30 1997-11-13 Schering Ag Neue Vitamin D-Derivate mit carbo- oder heterocyclischen Substituenten an C-25, Verfahren zu ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln
SG70010A1 (en) * 1996-05-23 2000-01-25 Hoffmann La Roche Fluorinated vitamin d3 analogs
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
CA2303248A1 (en) * 1997-09-08 1999-03-18 F. Hoffmann-La Roche Ag 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analogs
US6521608B1 (en) 1998-03-27 2003-02-18 Oregon Health & Science University Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders
US20030188756A1 (en) * 2002-08-19 2003-10-09 Cantorna Margherita T Treatment of inflammatory bowel disease with vitamin d compounds
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
US6358939B1 (en) 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20030220307A1 (en) * 2000-08-17 2003-11-27 Akira Kawase Remedial agent for osteoporosis
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7122542B2 (en) * 2003-07-30 2006-10-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
AU2006245283B2 (en) * 2005-05-10 2012-11-01 Dermipsor Ltd. Compositions and methods for treating hyperproliferative epidermal diseases
US8034788B2 (en) * 2005-05-10 2011-10-11 Dermipsor Ltd. Composition and methods for skin care
CA2607901C (en) 2005-06-13 2016-08-16 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine
ES2279500T3 (es) * 2005-06-17 2007-08-16 Magneti Marelli Powertrain S.P.A. Inyector de carburante.
DE602007012216D1 (de) * 2006-04-10 2011-03-10 Wisconsin Alumni Res Found 1-alpha-hydroxy-2-(3'-hydroxypropyliden)-19-nor-vitamin-d-verbindungen mit einer 1,1-dimethylpropyl-seitenkette
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US20080051375A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
EP2063963A2 (en) 2006-08-25 2009-06-03 Cougar Biotechnology, Inc. Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
SG173119A1 (en) * 2009-01-27 2011-08-29 Berg Biosystems Llc Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy
BR112012003372A2 (pt) 2009-08-14 2019-09-24 Berg Biosystems Llc vitamina d3 e análogos da mesma para o tratamento de alopecia.
WO2017209934A1 (en) 2016-05-13 2017-12-07 Case Western Reserve University Autophagy activators for treating or preventing skin injury
KR20240115925A (ko) 2016-07-29 2024-07-26 얀센 파마슈티카 엔브이 전립선암의 치료 방법
US10548908B2 (en) 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
US11903952B2 (en) 2020-05-27 2024-02-20 Northwestern University Vitamin D as an immune modulator to prevent immune-related complication from COVID-19 infection

Also Published As

Publication number Publication date
GR3020097T3 (en) 1996-08-31
CZ141694A3 (en) 1995-01-18
FI108226B (sv) 2001-12-14
NZ246052A (en) 1995-07-26
ES2089585T3 (es) 1996-10-01
TW275060B (sv) 1996-05-01
CN1035177C (zh) 1997-06-18
JP3280975B2 (ja) 2002-05-13
KR940703806A (ko) 1994-12-12
ZA929650B (en) 1993-06-09
MX9207101A (es) 1993-08-01
FI942766A (sv) 1994-06-10
CA2125476C (en) 2003-02-11
HU9401456D0 (en) 1994-08-29
WO1993012081A1 (de) 1993-06-24
JPH07505132A (ja) 1995-06-08
ATE138366T1 (de) 1996-06-15
EP0637299A1 (de) 1995-02-08
CZ286579B6 (cs) 2000-05-17
HUT68263A (en) 1995-06-28
EP0637299B1 (de) 1996-05-22
US5446035A (en) 1995-08-29
SK280450B6 (sk) 2000-02-14
IL104074A (en) 1998-01-04
AU4035693A (en) 1993-07-19
CN1073677A (zh) 1993-06-30
PL171403B1 (pl) 1997-04-30
DK0637299T3 (da) 1996-09-30
DE4141746A1 (de) 1993-06-17
DE59206393D1 (de) 1996-06-27
CA2125476A1 (en) 1993-06-24
KR100271462B1 (ko) 2000-11-15
AU670585B2 (en) 1996-07-25
NO942178L (sv) 1994-06-10
IL104074A0 (en) 1993-05-13
SK66194A3 (en) 1995-02-08
NO305949B1 (no) 1999-08-23
NO942178D0 (no) 1994-06-10

Similar Documents

Publication Publication Date Title
DE59206393D1 (de) 20-methyl-substituierte vitamin d-derivate
DK142987A (da) Hidtil ukendte vitamin d-analoger
NO951813L (no) Bicyklisk heterocyklisk sulfonamid og sulfonester-derivater
ATE45347T1 (de) Vitamin d3-derivate.
DE3575715D1 (de) Adamantanamin-derivate, verfahren zur herstellung und diese enthaltende heilmittel.
ES2126581T3 (es) Derivados de 3-(piperazino-alquil)indol condensados en posiciones 1,7, asi como procedimiento y productos intermedios para su preparacion y medicamentos que contienen estos compuestos.
ES464728A1 (es) Procedimiento para producir derivados del acido propionico
ES2072765T3 (es) Procedimiento para la obtencion de 5,6-dihidroxi-indolinas.
ES2155948T3 (es) 20-oxopregna-derivados 17-cadena lateral alquinilica de la vitamina d, metodos para su produccion y composiciones farmaceuticas de los mismos.
DE69415812D1 (de) 15,15-dialkylsubstituierte östradiolderivate
AU563426B2 (en) 3-alkoxy-2(n-pyrrolidino)-n-pyridyl-n-furyl (or thienyl) methyl propylamines
TW252976B (sv)
HUT35658A (en) Process for producing 7-oxo-prostacycline derivatives of selective biological activity
ES2059702T3 (es) Politioureas, procedimiento para su fabricacion y empleo de estas politioureas para evitar o reducir la formacion de costras en reactores.
GB1416929A (en) Fluoranthene derivatives
DK0746556T3 (da) Tricycliske forbindelser med affinitet for 5-HT1A-receptoren
ES2085544T3 (es) Procedimiento para la fabricacion de 8-n,n-dialquilaminotriciclo-(5.2.1.02,6)decano.
JPS5229251A (en) Support e1uipment for measurement instrument
FI921238A (sv) Som mellanprodukter användbara N'-alkoxi- eller N'-aralkyloxi-N6-cyano-griseolinsyraderivat
JPS53119874A (en) Preparation of 2-mercaptobenzimidazole type derivatives

Legal Events

Date Code Title Description
MA Patent expired